Literature DB >> 3379388

Is monoamine oxidase inhibitor induced myoclonus serotoninergically mediated?

J J Askenasy1, M D Yahr.   

Abstract

In the present study a single case observation of myoclonus during sleep-wave transition was monitored in a depressed patient treated with the monoamine oxidase inhibitor, phenelzine. The myoclonus had a rhythm of 1 c/second and lasted for two years, the duration of phenelzine treatment. Myoclonus appeared neither during wakefulness nor during sleep, but at wake-sleep-wake transitions. This "switch" myoclonus was associated with phasic muscle hyperactivity during REM sleep. Methysergide a 5-HT suppressor, decreased the switch myoclonus frequency and the REM muscle hyperactivity, indicating serotoninergic involvement in the mechanism of phenelzine induced myoclonus.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3379388     DOI： 10.1007/bf01244633

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  41 in total

1.  Receptor mechanisms in increased sensitivity to serotonin agonists after dihydroxytryptamine shown by electronic monitoring of muscle twitches in the rat.

Authors:  R M Stewart; A Campbell; G Sperk; R J Baldessarini
Journal:  Psychopharmacology (Berl)       Date:  1979-02-28       Impact factor: 4.530

2.  The syndrome of intention or action myoclonus as a sequel to hypoxic encephalopathy.

Authors:  J W LANCE; R D ADAMS
Journal:  Brain       Date:  1963-03       Impact factor: 13.501

3.  Comparison of antidepressant drugs in depressive illnesses.

Authors:  P J DALLY; P ROHDE
Journal:  Lancet       Date:  1961-01-07       Impact factor: 79.321

Review 4.  The clinical incidence of myoclonus.

Authors:  A M Halliday
Journal:  Mod Trends Neurol       Date:  1967

5.  The monoamine oxidases of brain: selective inhibition with drugs and the consequences for the metabolism of the biogenic amines.

Authors:  H Y Yang; N H Neff
Journal:  J Pharmacol Exp Ther       Date:  1974-06       Impact factor: 4.030

Review 6.  An animal behavior model for studying central serotonergic synapses.

Authors:  B L Jacobs
Journal:  Life Sci       Date:  1976-09-15       Impact factor: 5.037

Review 7.  Combined MAOI-tricyclic antidepressant treatment: a reevaluation.

Authors:  K White; G Simpson
Journal:  J Clin Psychopharmacol       Date:  1981-09       Impact factor: 3.153

8.  Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan.

Authors:  D G Grahame-Smith
Journal:  J Neurochem       Date:  1971-06       Impact factor: 5.372

9.  Suppression of REM rebound by Pergolide.

Authors:  J J Askenasy; M D Yahr
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

10.  Is the failure of (-)deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect?

Authors:  N Mendis; C M Pare; M Sandler; V Glover; G M Stern
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530
View more
  5 in total

1.  Different laws govern motor activity in sleep than in wakefulness.

Authors:  J J Askenasy; M D Yahr
Journal:  J Neural Transm Gen Sect       Date:  1990

2.  Parkinsonian tremor loses its alternating aspect during non-REM sleep and is inhibited by REM sleep.

Authors:  J J Askenasy; M D Yahr
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-09       Impact factor: 10.154

Review 3.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

Review 4.  Drug-induced myoclonus: frequency, mechanisms and management.

Authors:  Félix Javier Jiménez-Jiménez; Inmaculada Puertas; María de Toledo-Heras
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 5.  The clinical heterogeneity of drug-induced myoclonus: an illustrated review.

Authors:  Sabine Janssen; Bastiaan R Bloem; Bart P van de Warrenburg
Journal:  J Neurol       Date:  2016-12-16       Impact factor: 4.849
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.